Panel Discussion: Reducing Development Risk by Evaluating Genetic Editing Strategies Shaping the Future of TIL Therapies

• Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
• Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
• Identifying where genetic modification adds clear clinical value vs. added complexity
• Can TIL manufacturing be designed for in vivo development rather than culturing the cells in vitro?

Speakers:

Jessica Chacon

Assistant Professor

Texas Tech University Health Sciences Center

Andrew Weinberg

President & Chief Scientific Officer

AgonOx